BioCentury | Mar 6, 2021
Politics, Policy & Law

PTAB expected to get a Supreme pass

Whether the Supreme Court finds the Patent Trial and Appeal Board’s current structure to be unconstitutional may be down to a coin flip. Regardless of the outcome, it is likely that the inter partes...
BioCentury | Mar 6, 2021
Product Development

March 5 Quick Takes: A regulatory first for Actemra; plus updates from Lilly-Incyte, Kronos, Junshi, United Therapeutics, Pfizer, Sumitomo Dainippon, Arena, Oyster Point, Azura

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA approved Actemra tocilizumab to treat systemic sclerosis-associated interstitial lung disease, making it the first approved biologic for the disorder. FDA based the approval on data...
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

Last week’s FDA approval of Sarepta’s Amondys 45 marks the eighth new modality drug to be approved in the last year, a sign that the pace of new therapeutic formats making it to...
BioCentury | Mar 6, 2021
Emerging Company Profile

Araris: universal linkers for antibody-drug conjugates

Araris is developing antibody-drug conjugate linker technology that could widen the therapeutic window for ADCs by improving their stability and solubility. In addition, the Swiss biotech’s peptide linkers...
BioCentury | Mar 5, 2021
Deals

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

A year to the day after unveiling a $73 million series A round led by Omega Funds, immuno-oncology company Amunix Pharmaceuticals Inc. raised $117 million in a series B round led by Viking Global Investors...
BioCentury | Mar 3, 2021
Finance

March 3 Venture Roundup: Bionaut debuts with $20M; plus Janux, Century, Caribou, Medilink, Oxular and more

Bionaut Labs launched Wednesday with a $20 million round led by Khosla Ventures. Upfront Ventures, Revolution, Bold Capital and Compound also participated. The Los Angeles-based company is developing microscale robots to locally deliver biologics, nucleic...
BioCentury | Mar 3, 2021
Product Development

eGenesis $125M C round to support clinical trials of kidney, islet transplants from engineered pigs

eGenesis plans to bring its lead CRISPR-edited pig-to-human kidney and pancreatic islet transplant programs into the clinic and scale GMP production with its untranched $125 million series C financing.  Given the high unmet need for...
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical pipeline of AAV9-based gene therapies...
BioCentury | Feb 25, 2021
Finance

Foresite raises nearly $1B to back data science plays with fifth fund, incubator

With $969 million raised across two new funds, Foresite Capital plans to continue putting its money to work in data-driven healthcare companies. Foresite Capital Fund V and Foresite Capital Opportunity Fund V will invest in...
Items per page:
1 - 10 of 5075
BioCentury | Mar 6, 2021
Politics, Policy & Law

PTAB expected to get a Supreme pass

Whether the Supreme Court finds the Patent Trial and Appeal Board’s current structure to be unconstitutional may be down to a coin flip. Regardless of the outcome, it is likely that the inter partes...
BioCentury | Mar 6, 2021
Product Development

March 5 Quick Takes: A regulatory first for Actemra; plus updates from Lilly-Incyte, Kronos, Junshi, United Therapeutics, Pfizer, Sumitomo Dainippon, Arena, Oyster Point, Azura

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA approved Actemra tocilizumab to treat systemic sclerosis-associated interstitial lung disease, making it the first approved biologic for the disorder. FDA based the approval on data...
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

Last week’s FDA approval of Sarepta’s Amondys 45 marks the eighth new modality drug to be approved in the last year, a sign that the pace of new therapeutic formats making it to...
BioCentury | Mar 6, 2021
Emerging Company Profile

Araris: universal linkers for antibody-drug conjugates

Araris is developing antibody-drug conjugate linker technology that could widen the therapeutic window for ADCs by improving their stability and solubility. In addition, the Swiss biotech’s peptide linkers...
BioCentury | Mar 5, 2021
Deals

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

A year to the day after unveiling a $73 million series A round led by Omega Funds, immuno-oncology company Amunix Pharmaceuticals Inc. raised $117 million in a series B round led by Viking Global Investors...
BioCentury | Mar 3, 2021
Finance

March 3 Venture Roundup: Bionaut debuts with $20M; plus Janux, Century, Caribou, Medilink, Oxular and more

Bionaut Labs launched Wednesday with a $20 million round led by Khosla Ventures. Upfront Ventures, Revolution, Bold Capital and Compound also participated. The Los Angeles-based company is developing microscale robots to locally deliver biologics, nucleic...
BioCentury | Mar 3, 2021
Product Development

eGenesis $125M C round to support clinical trials of kidney, islet transplants from engineered pigs

eGenesis plans to bring its lead CRISPR-edited pig-to-human kidney and pancreatic islet transplant programs into the clinic and scale GMP production with its untranched $125 million series C financing.  Given the high unmet need for...
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical pipeline of AAV9-based gene therapies...
BioCentury | Feb 25, 2021
Finance

Foresite raises nearly $1B to back data science plays with fifth fund, incubator

With $969 million raised across two new funds, Foresite Capital plans to continue putting its money to work in data-driven healthcare companies. Foresite Capital Fund V and Foresite Capital Opportunity Fund V will invest in...
Items per page:
1 - 10 of 5075